Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1990 Nov;116(6):633–638. doi: 10.1007/BF01637086

Adriamycin uptake and metabolism in organotypic culture of A 549 human adenocarcinoma cells according to the exposure time

Sylvie Chevillard 1,2,✉, Philippe Vielh 3, Gerard Bastian 1,2, Jacques Coppey 1,4
PMCID: PMC12200419  PMID: 2254382

Abstract

In organotypic cultures (nodules) of A 549 human lung adenocarcinoma cells, the long-term cytotoxicity of Adriamycin is strongly improved by shortening the exposure time to the drug. In order to gain insight into the mechanisms of Adriamycin toxicity in this system, we have examined the drug uptake, retention and metabolism by fluorescence microscopy and HPLC analysis. A 549 nodules efficiently metabolize Adriamycin, two major metabolites, adriamycinol and an aglycone derivative, as yet chemically unidentified, are formed and efficiently excreted. Kinetic data show that a long exposure to Adriamycin triggers its efflux from both the nucleus and the cytoplasm while stimulating its metabolism. Therefore, a long exposure time to the drug appears to trigger a process of cellular detoxification by favouring its excretion from the cells via increased metabolism.

Key words: Adriamycin, metabolism, Detoxification, Organotypic culture

Abbreviations

ADR

Adriamycin

ADRol

adriamycinol

ADRx

an aglycone derivative

References

  1. Aubel-Sadron G, Londos-Gagliardi D (1984) Daunorubicin and doxorubicin, anthracycline antibiotics, a physiochemical and biological review. Biochimie 66:333–352 [DOI] [PubMed] [Google Scholar]
  2. Bachur NR, Gee M (1976) Microsomal reductive glycosidase. J Pharmacol Exp Ther 197:681–686 [PubMed] [Google Scholar]
  3. Baurain R, Zenebergh A, Trouet A (1978) Cellular uptake and metabolism of daunorubicin as determined by high pressure liquid chromatography: applications for L1210 cells. J Chromatogr 157:331–336 [DOI] [PubMed] [Google Scholar]
  4. Beaupain R, Dionet C (1985) Effects of combined treatments of cisdiamminedichloroplatinum (II), 5-fluorouracil and X rays on growth of human cancer nodules maintained in continuous organotypic cultures. Cancer Res 45:3150–3154 [PubMed] [Google Scholar]
  5. Beaupain R, Baroche C, Lagarde D (1983) Long term regeneration of cisplatinum and X-ray treated human tumor nodules in continuous organotypic culture. Int J Radiat Oncol Biol Phys 9:707–712 [DOI] [PubMed] [Google Scholar]
  6. Benjamin RS, Riggs CE, Bachur NR (1973) Pharmacokinetics and metabolism of Adriamycin in man. Clin Pharmacol Ther 14:592–600 [DOI] [PubMed] [Google Scholar]
  7. Benjamin RS, Riggs CE, Bachur NR (1977) Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37:1416–1420 [PubMed] [Google Scholar]
  8. Blum RH, Karter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249–259 [DOI] [PubMed] [Google Scholar]
  9. Bosanquet AG (1986). Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. Cancer Chemother Pharmacol 17:1–10 [DOI] [PubMed] [Google Scholar]
  10. Brenner DE (1987) Approaches to the problem of individual doxorubicin dosing schedules. Pathol Biol 35:31–39 [PubMed] [Google Scholar]
  11. Bristow MR, Billingham ME, Masson JW, Daniels JR (1978) Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep 62:873–879 [PubMed] [Google Scholar]
  12. Broggini M, Grandi M, Ubezio P, Geroni C, Guliani FC, D'Incalci M (1988) Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in drug-resistant subline. Biochem Pharmacol 37:4423–4431 [DOI] [PubMed] [Google Scholar]
  13. Calabresi P, Parks RE (1985) In: The Gilmas AG (ed) pharmacological basis of therapeutics, Macmillan, New York, 7th ed, chap 55. p 1283 [Google Scholar]
  14. Chauffert B, Martin F, Caignard A, Jeannin JF, Leclerc A (1984) Cytofluorescence localization of Adriamycin in resistant colon cancer cells. Cancer Chemother Pharmacol 13:14–18 [DOI] [PubMed] [Google Scholar]
  15. Deffie AM, Batra JK, Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P 388 leukemia cell lines. Cancer Res 49:58–62 [PubMed] [Google Scholar]
  16. Dimarco A (1975) Adriamycin (NSC 123127): mode and mechanism of action. Cancer Chemother Rep 6:91–106 [Google Scholar]
  17. Felsted RL, Gee M, Bachur NR (1974) Rat liver daunorubicin reductase an aldo-ketoreductase. J Biol Chem 249:3672–3679 [PubMed] [Google Scholar]
  18. Fiszer-Szafarz B, Szafarz D, Guevara de Murillo AA (1981) General fast and sensitive micromethod of DNA determination. Application to rat and mouse liver, rat hepatoma, human leucocytes, chicken fibroblasts, and yeast cells. Anal Biochem 110:165–170 [DOI] [PubMed] [Google Scholar]
  19. Gerlach JH, Kartner N, Bell R, Ling V (1986) Multidrug resistance. Cancer Surv 5:25–46 [PubMed] [Google Scholar]
  20. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM (1980) Evidence of a specific complex between Adriamycin and negatively charged phospholipids. Biochim Biophys Acta 597:1–14 [DOI] [PubMed] [Google Scholar]
  21. Gottesman MM, Pastan I (1988) Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol Sci 9:54–58 [DOI] [PubMed] [Google Scholar]
  22. Green RF, Collins JM, Jenkins JF, Speyer JL, Myers CE (1983) Plasma pharmacokinetics of Adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 43:3417–3421 [PubMed] [Google Scholar]
  23. Hahn GM, Ray GR, Gordon LF, Kallman RF (1973) Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2- and 24-h exposure. J Natl Cancer Inst 50:529–533 [DOI] [PubMed] [Google Scholar]
  24. Howell SK, Stephens LC, Wang YM (1989) Daunorubicin-induced mammary tumors in the rat. Eur J Cancer Clin Oncol 25:1549–1554 [DOI] [PubMed] [Google Scholar]
  25. Inaba M, Johnson RK (1978) Uptake and retention of Adriamycin and daunorubicin by sensitive and anthracycline resistant sublines of P388 leukemia. Biochem Pharmacol 27:2123–2130 [DOI] [PubMed] [Google Scholar]
  26. Krishan A, Ganapathi RN, Israel M (1978) Effect of Adriamycin and analogs on the nuclear fluorescence of propidium iodidestained cells. Cancer Res 38:3656–3662 [PubMed] [Google Scholar]
  27. Lieber M, Smith B, Szakal A, Nelson R, Todaro GA (1976) Continuous tumor cell line from a human carcinoma with properties of type 2 alveolar epithelial cells. Int J Cancer 17:62–67 [DOI] [PubMed] [Google Scholar]
  28. Loveless H, Arena E, Felsted RL, Bachur NR (1978) Comparative mammalian metabolism of Adriamycin and daunorubicin. Cancer Res 38:589–593 [PubMed] [Google Scholar]
  29. Mitzuno NS, Zakis B, Decker RW (1978) Binding of daunorubicin to DNA and the inhibition of RNA and DNA synthesis. Cancer Res 38:593–598 [PubMed] [Google Scholar]
  30. Myers C (1986) Anthracyclines. In: Pinedo HM and Chabner BA (eds) Cancer Chemotherapy, Vol 8. The EORTC Cancer Chemotherapy Annual, Chap 3. Elsevier, Amsterdam, p 52 [Google Scholar]
  31. Noel G, Peterson C, Trouet A, Tulkens P (1978) Uptake and subcellular localization of daunorubicin and Adriamycin in cultured fibroblasts. Eur J Cancer 14:363–368 [DOI] [PubMed] [Google Scholar]
  32. Pastan I, Gottesman M (1987) Multiple drug resistance in human cancer. N Engl J Med 316:1388–1393 [DOI] [PubMed] [Google Scholar]
  33. Peterson C, Trouet A (1978) Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts. Cancer Res 38:4645–4649 [PubMed] [Google Scholar]
  34. Ramu A, Pollard HB, Rosario LM (1989) Doxorubicin resistance in P 388 leukemia evidence for reduced drug influx. Int J Cancer 44:539–547 [DOI] [PubMed] [Google Scholar]
  35. Robert J (1980) Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liq Chromatogr 3:1561–1572 [Google Scholar]
  36. Roninson IB (1987) Molecular mechanism of multidrug resistance in tumor cells. Clin Physiol Biochem 5:140–151 [PubMed] [Google Scholar]
  37. Seeber S, Asieka R, Schmidt CG, Achterrath W, Crooke GT (1982) In vivo resistance towards anthracyclines etoposide andcis-diaminedichloroplatinum. Cancer Res 42:4719–4725 [PubMed] [Google Scholar]
  38. Sobrero A, Bertino JR (1986) Clinical aspects of drug resistance. Cancer Surv 5:93–107 [PubMed] [Google Scholar]
  39. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D (1979) Resistance to Adriamycin in muticellular spheroids. Int J Radiat Oncol Biol Phys 5:1225–1230 [DOI] [PubMed] [Google Scholar]
  40. Takanashi S, Bachur NR (1976) Adriamycin metabolism in man, evidence from urinary metabolites. Drug Metab Dispos 4:79–87 [PubMed] [Google Scholar]
  41. Tritton TR, Hickman JA (1985) Cell surface membranes as chemotherapeutic target. In: Muggia FM (ed) Chemotherapy, Vol 2. Martinus Nijhoff, The Hague, p81–131 [Google Scholar]
  42. Tritton TR, Yee G (1982) The anticancer agent doxorubicin can be actively cytotoxic without entering cells. Science 217:248–250 [DOI] [PubMed] [Google Scholar]
  43. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46:5941–5946 [PubMed] [Google Scholar]
  44. Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Eng J Med 305:139–153 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES